Tuesday , December 10 2019
Home / indonesia / Succeeding Bio Farma Level 1 new disease of new disease

Succeeding Bio Farma Level 1 new disease of new disease



TEMPO.CO, The Bandung – A new typhoid vaccine from research by Bio Farma, the University of Indonesia, Rumah Sakti Cipto Mangunkusumo, and the International Vaccine Institute (IVI) Korea have passed a Clinical Stage 1 Test.

LEABH: Minister of Directors of SOEs of Pindad and Bio Farma Renewables

"In conjunction with IVI and experts from a number of universities in Indonesia, we will complete a clinical trial development program so that your tepho vaccine is related to meeting the needs of people as soon as possible able and provides comprehensive protection to the community, "said Adriansjah Azhari, Bio Farma's Planning and Development Director, drawn from the journalist Bio Farma received by Tempo, Friday, February 22, 2019.

Step 1 Clinical Case An immunization vaccine, is a typhoid Commonwealth that includes adults and children in Indonesia. The result of these clinical trials has concluded that their vaccine is safe and can result in a defensive protection response. The development of a vaccine is done by moving technology to vaccine and antiserary agents in Indonesia. At this time, the study of a new vaccine at Phase II immunization of a typhoid is going on.

"We are proud of its successful collaboration with the team from the Indonesia University / Cipto Mangunkusumo Hospital and our partners from IVI, and thus provide very good results from this stage. learning. This is an important achievement in our efforts to develop a new herbal vaccine, "said Head of Department of Clinical Inspection and Examinations, Bio Farma, Novilia Sjafri Bachtiar, announced from the distribution, Friday, February 22, 2019.

LEABH: The Bio Farma Targets for the Birth of Latest Illness is completed in 2019

IVI Director, Jerome Kim, said the new vaccine's research was to protect the route for more clinical trials. "Research also facilitates other clinical tests of this vaccine, so that the conjugate tepho vaccine can enter the market faster," he said, Friday 22 February 2019.

IVI Typhoid program director Sushant Sahastrabuddhe said that this research is also an important step in developing a new type of tepho vaccine. The research aims to look at the financial aspects and immunogenicity of a new conjugate tepide VI-DT vaccine. This product is that vaccines for vaccines are safe and immunogenic in adults and children over 2 years. "This research is an important step in the development of a VI-DT typhoid vaccine that can protect the world, especially those that are most vulnerable to tephoid infection, children," said Susunt, Friday 22nd February 2019.

Tephoid fever that causes Salmonella typhi bacteria is still regarded as one of the main causes of death, with the number of deaths that occur; reaching 200,000 people per year in the world. Typhoid fever also affects children, especially in endemic areas. Typhoid vaccine is one way to prevent this disease, but it is not possible to prevent this disease; Praising current typhoid vaccine for under-fives.

Read news about Bio Farma Tempo.coSouth Westerly


Source link